BioVersys
Privately held Swiss biopharmaceutical company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | N/A | CHF80.0m Valuation: CHF213m 117.1x EV/Revenue -9.0x EV/EBITDA | IPO |
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2018 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 1 % | (8 %) | 4 % | - | 67 % | 300 % | 38 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (1508 %) | (1294 %) | (306 %) | (276 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (1558 %) | (1288 %) | (293 %) | (289 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
BioVersys is a Swiss pharmaceutical company based in Basel, specializing in the research and development of small molecules targeting antimicrobial resistance (AMR). The company focuses on creating therapies that address bacterial infections through novel modes of action and targets. BioVersys operates in the pharmaceutical and biotech sectors, serving healthcare systems globally by providing solutions to combat the silent pandemic of AMR. The business model revolves around advancing clinical trials and bringing effective treatments to market, thereby generating revenue through the commercialization of its pharmaceutical products. The company is governed by a board of directors with extensive experience in the pharma and biotech industries, ensuring strategic oversight and guidance. BioVersys is committed to improving patient outcomes and safeguarding global health by addressing one of the most pressing medical threats of our time.
Keywords: antimicrobial resistance, small molecules, bacterial infections, pharmaceutical, biotech, clinical trials, healthcare, global health, therapies, Basel